Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06584942 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)
A Phase 4 study of Cannabis Use Disorder and Orexin Antagonist, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06584942 is a Phase 4 study of Cannabis Use Disorder and Orexin Antagonist that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06584942, a Phase 4 study of Cannabis Use Disorder and Orexin Antagonist, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to observe the impact of suvorexant, sold as BELSOMRA, on brain activity of people who frequently use cannabis. Suvorexant is an FDA-approved medication to treat insomnia. Researchers think that suvorexant may reduce activity in certain parts of the brain associated with cannabis use. Researchers are studying if this medication does affect brain activity in these areas. For this study, participants will be asked to complete four study visits over approximately 14 days. Each study visit will include interviews, questionnaires, and collection of biological samples for laboratory testing. All participants will be asked to take suvorexant, an FDA approved medication for treatment of insomnia, for 14 days. They will complete two one-hour functional Magnetic Resonance Imaging (fMRI) scans: one before starting the study medication and one after 14 days of taking the study medication. MRI is used in typical medical settings and is considered to be safe. Participants will also be asked to complete a short daily survey for approximately 14 days.
Conditions Studied
Interventions
- DRUG Suvorexant
Study Locations (1)
Massachusetts
- Center for Addiction Medicine, Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06584942
The ClinicalTrials.gov registry entry for NCT06584942 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (82% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cannabis Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Suvorexant is the first listed.
NCT06584942 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06584942 about?
NCT06584942 is a clinical study titled "Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)". The goal of this study is to observe the impact of suvorexant, sold as BELSOMRA, on brain activity of people who frequently use cannabis. Suvorexant is an FDA-approved medication to treat insomnia. Researchers think that suvorexant may reduce activity in certain parts of the brain associated with ca...
What is the current status of trial NCT06584942?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-03-10. Estimated completion is 2026-07.
What conditions does trial NCT06584942 study?
This clinical trial studies the following conditions: Cannabis Use Disorder, Orexin Antagonist, Cue-reactivity, Functional MRI.
What interventions are being tested in trial NCT06584942?
The interventions under investigation include: Suvorexant (DRUG).
Who is sponsoring clinical trial NCT06584942?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06584942 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing Cannabis Overuse With Prazosin
COMPLETED · Phase 4
-
Bupropion for ADHD in Adolescents With Substance Use Disorder
COMPLETED · Phase 4
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
Psilocybin-assisted Treatment for Cannabis Use Disorder
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.